$IMDX Cashflow Statement | Understand Stock

$IMDX

$3.18 +$0.00 (0.0%) Close

$IMDX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense
Depreciation and amortization expense
Amortization of intangible assets
Impairment charge for long-lived assets
Pro rata loss from equity method investment in Razor
Stock-based compensation
Loss on marketable equity securities
Amortization of debt issuance costs
Equity compensation for bonus awards and consulting services
Change in fair value of contingent consideration
Deferred income tax benefit
Gain on extinguishment of debt (PPP loan)
Impairment losses
Goodwill impairment
Loss on disposal of discontinued operations
Impairment loss on held for sale assets
Impairment loss from held for sale assets of discontinued operations (Note 13)
Unrealized foreign currency losses (gains)
Changes in operating assets and liabilities:
Accounts receivable
Inventories
Prepaid expenses and other assets
Accounts payable and accrued liabilities
Accrued severance from Chronix Biomedical acquisition
Accrued severance and liabilities from Chronix Biomedical acquisition
Operating lease assets and liabilities

Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of Insight Genetics, net of cash acquired
Acquisition of Razor Genomics asset, net of cash acquired
Acquisition of Chronix Biomedical, net of cash acquired
Proceeds from sale of marketable equity securities
Proceeds from sale of equipment
Machinery and equipment purchases, and construction in progress
Cash sold in discontinued operations (Note 13)
Net cash used in investing activities

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of stock options
Proceeds from sale of common shares
Financing costs to issue common shares
Proceeds from exercise of warrants
Common shares received and retired for employee taxes paid
Proceeds from sale of redeemable convertible Series A preferred shares
Proceeds from sale of common shares under at-the-market transactions
Financing costs for at-the-market sales
Redemption of Series A redeemable convertible preferred shares
Financing costs to issue redeemable convertible Series A preferred shares
Repayment of bank loan
Contingent consideration liability payments
Taxes paid related to net share settlement of stock-based awards
Repayment of financing lease obligations
Net provided by financing activities

Effect of exchange rate changes on cash and cash equivalents
NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest
Cash paid for income taxes
SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES
Common stock issued for acquisition of Razor Genomics assets
Common stock issued for acquisition of Razor Genomics asset
Deferred tax liability generated from the acquisition of Razor Genomics asset
Common stock issued for acquisition of Chronix Biomedical
Deferred tax liability generated from the acquisition of Chronix
Initial fair value of contingent consideration at acquisition date
Assumed liability from Chronix Acquisition
Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability
Construction in progress, machinery and equipment purchases included in accounts payable and accrued liabilities
Machinery and equipment purchases, and construction in progress included in accounts payable and accrued liabilities
Accretion of Series A convertible preferred stock
Lease assets obtained in exchange for lease liabilities

Comments